The following is a summary of the TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript:

Financial Performance:

• TG Therapeutics reported total revenue for Q1 2024 of $63.5 million, with U.S. Briumvi net product revenue accounting for $50.5 million.

• The company's operating expenses were approximately $58 million, leading to a slight net loss around $10.7 million, or $0.07 per share.

• As of Q1 2024, TG Therapeutics had a cash, cash equivalents, and investment securities total of $209.8 million.

• Full-year guidance has been adjusted to $270 million - $290 million due to current trends and robust growth.

Business Progress:

• TG Therapeutics secured the VA contract for Briumvi, opening it up to more healthcare providers.

• The company has newly issued patents extending protection for Briumvi through 2042, expanding future potential for the drug.

• The partnership with Precision BioSciences offers potential treatment for certain autoimmune diseases, expanding TG Therapeutics' reach.

• TG Therapeutics is focusing on increasing the convenience of Briumvi with the development of a subcutaneous version.

• The company expects to start clinical trials for azer-cel, an allogeneic CD19 CAR T cell therapy for autoimmune diseases and other non-oncology indications, within the year.

• Approximately 160 new prescribers and 65 new accounts were added in the first quarter, with broad adoption occurring in over 450 centers and over 800 unique prescribers.

• Plans to continue investment in Briumvi's launch are underway, projecting further profitability in coming quarters.

More details: TG Therapeutics IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.